HRTX vs. MRSN, ORGO, BMEA, ESPR, CRBP, RVNC, PEPG, ANNX, NGNE, and NKTX
Should you be buying Heron Therapeutics stock or one of its competitors? The main competitors of Heron Therapeutics include Mersana Therapeutics (MRSN), Organogenesis (ORGO), Biomea Fusion (BMEA), Esperion Therapeutics (ESPR), Corbus Pharmaceuticals (CRBP), Revance Therapeutics (RVNC), PepGen (PEPG), Annexon (ANNX), Neurogene (NGNE), and Nkarta (NKTX). These companies are all part of the "pharmaceutical preparations" industry.
Heron Therapeutics (NASDAQ:HRTX) and Mersana Therapeutics (NASDAQ:MRSN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.
In the previous week, Heron Therapeutics had 11 more articles in the media than Mersana Therapeutics. MarketBeat recorded 11 mentions for Heron Therapeutics and 0 mentions for Mersana Therapeutics. Heron Therapeutics' average media sentiment score of 0.71 beat Mersana Therapeutics' score of 0.00 indicating that Heron Therapeutics is being referred to more favorably in the media.
Heron Therapeutics has a beta of 1.68, suggesting that its stock price is 68% more volatile than the S&P 500. Comparatively, Mersana Therapeutics has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500.
Heron Therapeutics has a net margin of -87.02% compared to Mersana Therapeutics' net margin of -465.80%. Heron Therapeutics' return on equity of 0.00% beat Mersana Therapeutics' return on equity.
Heron Therapeutics presently has a consensus target price of $5.50, suggesting a potential upside of 124.49%. Mersana Therapeutics has a consensus target price of $6.29, suggesting a potential upside of 113.80%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Heron Therapeutics is more favorable than Mersana Therapeutics.
80.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 93.9% of Mersana Therapeutics shares are owned by institutional investors. 6.4% of Heron Therapeutics shares are owned by company insiders. Comparatively, 12.5% of Mersana Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Heron Therapeutics has higher revenue and earnings than Mersana Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Mersana Therapeutics, indicating that it is currently the more affordable of the two stocks.
Heron Therapeutics received 409 more outperform votes than Mersana Therapeutics when rated by MarketBeat users. Likewise, 68.95% of users gave Heron Therapeutics an outperform vote while only 65.78% of users gave Mersana Therapeutics an outperform vote.
Summary
Heron Therapeutics beats Mersana Therapeutics on 13 of the 18 factors compared between the two stocks.
Get Heron Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Heron Therapeutics Competitors List
Related Companies and Tools
